{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000033","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.370199+00:00","generated_at":"2026-05-17T01:17:42.362574+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio Reports Preclinical Data for IBIO-610 Showing Extended Half-Life in Obese Non-Human Primates","bullets":["IBIO-610 half-life in obese NHP measured at 33.2 days.","Predicted human half-life up to 100 days, enabling twice-yearly dosing.","Data to be presented at ObesityWeek 2025, Nov 4-7 in Atlanta by Cory Schwartz, Ph.D.","IBIO-610 is a potential first-in-class Activin E antibody for fat-selective weight loss.","Previously showed GLP-1-synergistic weight loss and prevention of weight regain in mouse models."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000033","json":"https://secwatch.observer/filing/0001420720-25-000033.json","markdown":"https://secwatch.observer/filing/0001420720-25-000033.md","text":"https://secwatch.observer/filing/0001420720-25-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000033/0001420720-25-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000033/ibio-20251030x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T01:17:42.362574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}